Want to see TSE:FRX full AI Analyst Report?
FRX Stock Chart & Stats
C$13.95
-C$0.70(-4.78%)
At close: 4:00 PM EDT
C$13.95
-C$0.70(-4.78%)
Day’s Range― - ―
52-Week RangeC$7.59 - C$16.10
Previous CloseN/A
Volume1.00
Average Volume (3M)639.00
Market Cap
C$560.23M
Enterprise ValueC$178.44
Total Cash (Recent Filing)C$40.18M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 05, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding34,737,030
10 Day Avg. Volume82
30 Day Avg. Volume639
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.28
Price to Sales (P/S)4.93
P/FCF Ratio-17.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$21.60Price Target Upside54.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.36
Revenue Forecast (FY)C$94.15M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue GrowthVery high gross margins (~92%) combined with sustained revenue growth (TTM ~$51.2M; Q2 +78% YoY) indicate attractive product economics and pricing power. These durable margins mean incremental sales should meaningfully improve profitability as adoption scales, supporting long-term operating leverage.
Debt-free Balance Sheet And Solid EquityA debt-free balance sheet with positive equity materially lowers financial risk and enhances flexibility. This structural strength lets management fund commercial expansion and weather cash-timing volatility without immediate refinancing, improving the company’s ability to execute multi-quarter commercialization plans.
Commercial Expansion And Evidence GenerationRapidly expanded sales coverage and medical affairs (broader prescriber targets, large jump in sales calls, increased HCP/site reach) plus active ISTs and ASCO data build both distribution and clinical credibility. This combination creates durable channels for adoption and a pathway to guideline-driven, sustained uptake over time.
Bears Say
Ongoing Cash Burn And Cash-flow VolatilityPersistent negative operating and free cash flow (TTM ~- $7.9M, worse in 2025) and quarter-to-quarter cash timing swings limit self-funding capacity. Continued burn increases reliance on product revenue growth or external capital and constrains discretionary investment if collections or sales slow.
Revenue Concentration By Tumor TypesHigh concentration (~80% in three tumor types) creates structural revenue vulnerability: changes in treatment patterns, guideline shifts, or payer decisions in any of these indications could materially impact sales. Diversifying indications and payers is required to reduce this durable single-indication exposure.
Dependence On Additional Clinical Data For Broader AdoptionManagement explicitly ties guideline upgrades, label expansion and broader adoption to mature IST and trial data, with no timeline. That clinical dependency is a structural constraint on TAM expansion; until evidence and guideline changes materialize, penetration beyond core pediatric/AYA segments may be limited.
Fennec Pharmaceuticals News
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.59 and its highest was C$16.10 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$560.23M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 86 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported C$0.077 earnings per share for the quarter, beating the consensus estimate of C$0.028 by C$0.049.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.12.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of C$0.077 in its last earnings report, beating expectations of C$0.028. Following the earnings report the stock price went up 36.315%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$21.60 (54.81% Upside)
C$21.60 (54.81% Upside)
Blogger Sentiment
Neutral
TSE:FRX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit and sequential revenue growth (+78% YoY in Q2), return to positive adjusted EBITDA, record operational metrics in July, expanded commercial reach and multiple ISTs with notable forthcoming data (SIOP oral presentation). These positives are tempered by higher SG&A and marketing-driven OpEx, short-term cash timing volatility, reliance on a concentrated set of tumor types for the majority of sales, and the need for additional clinical data to drive guideline upgrades and label expansion. Management is bullish on continued growth but remains conservative on formal revenue guidance until further traction and data maturity are achieved.View all TSE:FRX earnings summariesFRX Stock 12 Month Forecast
Average Price Target
C$21.60
▲(54.81% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―